# reload+after+2024-01-21 09:43:17.138955
address1§Connaught House
address2§1 Burlington Road Dublin 4
city§Dublin
zip§D04 C5Y6
country§Ireland
phone§353 1 772 8000
website§https://www.alkermes.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
fullTimeEmployees§2280
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Richard F. Pops', 'age': 61, 'title': 'Chairman & CEO', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 2304512, 'exercisedValue': 5146380, 'unexercisedValue': 1569123}, {'maxAge': 1, 'name': 'Mr. Iain Michael Brown', 'age': 54, 'title': 'Senior VP & CFO', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 867750, 'exercisedValue': 0, 'unexercisedValue': 400746}, {'maxAge': 1, 'name': 'Mr. Blair C. Jackson', 'age': 50, 'title': 'Executive VP & COO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1047250, 'exercisedValue': 652850, 'unexercisedValue': 466929}, {'maxAge': 1, 'name': 'Mr. David Joseph Gaffin', 'age': 51, 'title': 'Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 1075851, 'exercisedValue': 0, 'unexercisedValue': 525689}, {'maxAge': 1, 'name': 'Dr. Craig C. Hopkinson M.D.', 'age': 55, 'title': 'Executive VP of Research & Development and Chief Medical Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1124050, 'exercisedValue': 0, 'unexercisedValue': 795614}, {'maxAge': 1, 'name': 'Dr. Floyd E. Bloom M.D.', 'age': 86, 'title': 'Founder', 'yearBorn': 1937, 'fiscalYear': 2022, 'totalPay': 57728, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas  Harvey', 'title': 'Chief Information Officer & Senior VP of IT', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sandra  Coombs', 'title': 'Senior Vice President of Corporate Affairs & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael J. Landine', 'age': 69, 'title': 'Senior VP of Corporate Development & Chief Risk Officer', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 750463, 'exercisedValue': 234463, 'unexercisedValue': 514310}, {'maxAge': 1, 'name': 'Mr. Stephen  Schiavo', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§7
compensationRisk§3
shareHolderRightsRisk§3
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.551
priceToSalesTrailing12Months§2.996422
currency§USD
dateShortInterest§1702598400
forwardEps§2.43
pegRatio§0.68
exchange§NMS
quoteType§EQUITY
shortName§Alkermes plc
longName§Alkermes plc
firstTradeDateEpochUtc§679671000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§292fcc8e-3551-3f1c-b4a6-cd1ad786bd09
gmtOffSetMilliseconds§-18000000
targetHighPrice§42.0
targetLowPrice§25.0
targetMeanPrice§33.27
targetMedianPrice§34.0
recommendationMean§2.4
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§2.444
grossMargins§0.85106003
ebitdaMargins§0.18674
trailingPegRatio§None
